A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma

Over the past decade, therapies targeting the VEGF/VEGFR and mTOR pathways have served as the standard of care for the clinical management of renal cell carcinoma (RCC) patients. Albeit promising, these targeted drugs have attained only modest clinical benefits with limited prolonged progression-fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jingya, Wang, Xin, Tang, Boyun, Liu, Hongchun, Zhang, Minmin, Wang, Yueqin, Ping, Fangfang, Ding, Jian, Shen, Aijun, Geng, Meiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010995/
https://www.ncbi.nlm.nih.gov/pubmed/29930727
http://dx.doi.org/10.7150/thno.23964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010995/
https://www.ncbi.nlm.nih.gov/pubmed/29930727
http://dx.doi.org/10.7150/thno.23964

Ejemplares similares